Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease.
Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease.
复制标题
DOI：
10.3390/ph6101304
复制
发表时间：
2013-10-11
期刊：
影响因子：
--
通讯作者：
Ballard C
中科院分区：
文献类型：
--
作者：
Corbett A;Williams G;Ballard C
阿尔茨海默病（AD）是痴呆症的最常见原因，影响全球3500万患有该病症的人中的约三分之二。尽管如此，仍然缺乏有效的治疗方法，也没有药物可以产生疾病改善作用来改善结果。迫切需要开发和评估更有效的药物治疗。药物重新定位提供了一个令人兴奋的机会，将现有的许可治疗方法重新用于AD，其好处是提供了比通过新药发现方法更快的临床途径。本综述概述了目前最有希望的候选人重新定位在AD，他们的支持证据和他们的进展，通过审判的日期。此外，它开始探索新的转录组学和微阵列技术的潜力，以考虑未来的药物重新定位作为一种可行的药物发现方法。
Alzheimer’s Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an urgent need to develop and evaluate more effective pharmacological treatments. Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches. This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date. Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery.